

Preparation of 3-Acyl-4-aryl-coumarins via Metal-free Tandem Oxidative Acylation/Cyclization between Alkynoates with Aldehydes

Xia Mi, Chenyang Wang, Mengmeng Huang, Yusheng Wu, and Yangjie Wu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jo502220b • Publication Date (Web): 03 Dec 2014

Downloaded from <http://pubs.acs.org> on December 9, 2014

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.




Preparation of 3-Acyl-4-aryl-coumarins via Metal-free Tandem Oxidative Acylation/Cyclization between Alkynoates with Aldehydes

Xia Mi,[†] Chenyang Wang,[†] Mengmeng Huang,^{*,†} Yusheng Wu,^{*,†} and Yangjie Wu^{*,†}

[†]College of Chemistry and Molecular Engineering, Henan Key Laboratory of Chemical Biology and Organic Chemistry, Key Laboratory of Applied Chemistry of Henan Universities, Zhengzhou University, Zhengzhou 450052, P. R. China, wj@zzu.edu.cn, hmm@zzu.edu.cn

[‡]Tetranov Biopharm, LLC. 75 Daxue Road, Zhengzhou 450052, P.R. China, yusheng.wu@tetranovglobal.com



ABSTRACT

A new and efficient metal-free tandem acylation/cyclization of alkynoates with aldehydes was developed for the synthesis of 3-acyl-4-aryl-coumarins. The reaction was achieved by the addition of acyl radical to alkynes and a C-H bond functionalization to form two new C-C bonds simultaneously.





INTRODUCTION

Coumarins, an important class of heterocycles, are commonly found in natural compounds¹, pharmaceuticals², dyes³, and as versatile synthetic blocks⁴ in organic synthesis. Among these compounds, 3-acyl derivatives (coumarin-chalcone hybrid compounds) have received considerable attention since they display important biological activities⁵ such as antioxidant activity, monoamine oxidase (MAO) inhibitor, antimalarial, antitumor, and antiinflammatory. Because of these important applications, various methods for their synthesis have been reported (Fig. 1, eqn (1), (2), (3), (4)).^{6,7,8,9} However, these protocols can suffer from several drawbacks, such as inaccessible substrates and catalysts, tedious performances, hazardous reagents, low atom economy, and limited substrate scope. Therefore, the development of general, highly efficient and direct strategies to access 3-acylcoumarins is still desirable in synthetic chemistry.


Recently, oxidative coupling involving a C-H functionalization process has begun to emerge as an alternative route for C-C bond formation.¹⁰ The current

1
2
3 protocol enables the direct construction of target molecules by avoiding the
4 prefunctionalization of the coupling partners, and serves as an elegant example
5 of an atom economy approach. A lot of efforts have been devoted to the
6 oxidative coupling with an aldehyde C(sp²)-H bond to introduce a carbonyl
7 group, and significant improvements have been made in recent years. Many
8 groups successfully developed the transition-metal-catalyzed direct arylation of
9 aldehydes.¹¹ The direct oxidative coupling of aldehyde C(sp²)-H bonds with
10 alkenes has been employed to furnish saturated ketones¹², β-peroxy ketones¹³ or
11 unsaturated ketones¹⁴. In addition, alkynes have been widely used in oxidative
12 transformations catalyzed by the transition-metal complexes (especially Rh^I
13 catalysts) to obtain the α-alkenyl ketones via hydroacylation.¹⁵ Recently,
14 transition-metal-free cross-coupling has been employed as an environmentally
15 friendly and alternative approach to the metal catalyzed/mediated
16 transformations.¹⁶ In this context, Liang and Li respectively demonstrated the
17 tandem oxidative coupling of alkynes with aldehydes via a
18 single-electron-transfer (SET) process to produce fluorine and
19 3-acylspiro[4,5]trienone derivatives.¹⁷ Inspired by these works and based on
20 our previous study,¹⁸ herein, we describe a metal-free TBAB-mediated
21 oxidative tandem coupling of alkynoates with aldehydes for selective synthesis
22 of biologically attractive 3-acylcoumarins (Fig. 1, eqn (5)). This method was
23 achieved by sequential acylation and carbocyclization to form two new C-C
24 bonds simultaneously, providing a new, efficient and atom-economic route to
25 3-acyl-4-aryl-coumarins.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Previous work




This work

**Figure 1** Synthesis of 3-acylcoumarins**RESULTS AND DISCUSSION**

At the outset of our investigation, the reaction conditions were optimized by using phenyl 3-phenylpropiolate (**1a**) and diethyl *p*-tolualdehyde (**2a**). According to the protocol by Liang et al. on fluorine derivatives formation from TBHP/PivOH system,^{17a} the desired product **3a** was only obtained in 37% yield (Table 1, entry 1). Fortunately, the first breakthrough was achieved when we replaced PivOH with TBAB as an additive (Table 1, entry 2). Next, various oxidants were examined in the presence of TBAB, and K₂S₂O₈ was found to be the most efficient oxidant for this reaction (Table 1, entries 3-5). Other quaternary ammonium salts (Bu₄NF, Bu₄NCl, and Et₄NBr) led to a slight decrease in product yield of **3a** (Table 1, entries 6-8). Notably, *n*-Bu₄NI as an efficient catalyst¹⁹ in radical chemistry showed negligible activity (Table 1, entry 9), and no product **3a** was formed without TBAB (Table 1, entry 10). Various solvents were also surveyed, revealing that DCE is the best suited solvent as compared to other solvents such as CH₃CN, dioxane, toluene,

chlorobenzene and H₂O (Table 1, entries 11-15). The yield was increased to 73% by using 4 equiv of **2a** (Table 1, entry 16). Lowering the reaction temperature to 90 °C was feasible, however, reducing further to 80 °C led to a lower yield (Table 1, entries 17, 18). The yields were markedly decreased when the amount of TBAB was reduced to 0.5 equiv (Table 1, entry 19). In addition, the structure of **3a** was confirmed by X-ray analysis (see supporting information).²⁰

Table 1. Optimization of Conditions^a



entry	additive	oxidant	yield ^b (%)
1 ^c	PivOH	TBHP	37
2 ^c	TBAB	TBHP	51
3	TBAB	K ₂ S ₂ O ₈	59
4	TBAB	Na ₂ S ₂ O ₈	55
5	TBAB	(NH ₄) ₂ S ₂ O ₈	55
6	TBAC	K ₂ S ₂ O ₈	57
7	TBAF	K ₂ S ₂ O ₈	34
8	TEAB	K ₂ S ₂ O ₈	52
9	TBAI	K ₂ S ₂ O ₈	trace
10	-	K ₂ S ₂ O ₈	nr
11 ^d	TBAB	K ₂ S ₂ O ₈	nr
12 ^e	TBAB	K ₂ S ₂ O ₈	nr
13 ^f	TBAB	K ₂ S ₂ O ₈	17
14 ^g	TBAB	K ₂ S ₂ O ₈	25

15 ^h	TBAB	K ₂ S ₂ O ₈	32
16 ⁱ	TBAB	K ₂ S ₂ O ₈	73
17 ^{i,j}	TBAB	K ₂ S ₂ O ₈	75
18 ^{i,k}	TBAB	K ₂ S ₂ O ₈	62
19 ^{i,l}	TBAB	K ₂ S ₂ O ₈	65


^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.5 mmol), additive (0.25 mmol), oxidant (0.5 mmol), 1,2-dichloroethane (DCE, 1.5 mL) in a sealed tube under N₂ at 100 °C (oil bath) for 24 h, PivOH: pivalic acid; TBAF: *n*-Bu₄NF; TBAC: *n*-Bu₄NCl; TBAB: *n*-Bu₄NBr; TBAI: *n*-Bu₄NI; TEAB: Et₄NBr. ^b Isolated yields. ^c 70 % aq. ^d CH₃CN as solvent. ^e Dioxane as solvent. ^f Toluene as solvent. ^g Chlorobenzene as solvent. ^h H₂O as solvent. ⁱ 4 equiv of **2a** (2.0 mmol). ^j 90 °C (oil bath). ^k 80 °C (oil bath). ^l 0.5 equiv TBAB.

Under the optimal conditions, various aldehydes were firstly evaluated with phenyl 3-phenylpropiolate (**1a**). As demonstrated in Scheme 1, the metal-free acylation/cyclization reaction could proceed well to give corresponding products in moderate to good yields. The substrates bearing electron-donating groups at the *para*-position of the aromatic rings work more efficiently than those bearing electron-withdrawing groups (**3a-3g**) except product **3d**. Although *meta*-substituted benzaldehydes were also suitable for this transformation, generally, a slight decrease in product yields was found (**3h-3k**). Due to the steric effect, *ortho*-substituted benzaldehydes gave target products only in moderate yields (**3l-3n**). Alkyl and cyclic aldehydes could also be used as the coupling partners to provide the corresponding products in moderate yields (**3o-3q**).

Encouraged by above results, we next focused our attention on the scope of aryl alkynoates (Scheme 2). Generally, the reactions with either electron-rich or electron-poor groups at the 4-positions of phenoxy ring proceeded well, and the corresponding products were furnished in good yields except **4c** (**4a-4g**). With a strong electron-withdrawing group (CF₃) on the phenoxy ring, the product **4g** was only obtained in 38% yield. It was found that the steric effect on the phenoxy ring was distinct. A moderate yield (57%) was obtained with the reaction of 3,5-dimethyl substituted aryl phenylpropiolate (**4i**). Furthermore, no product was formed for *ortho*-substituted system (**4j**). Upon using substrates with methyl group at the *meta*-position of the phenoxy ring, a mixture of two regioisomers **4k** and **4k'** were formed in a ratio of 1.6:1, however, aryl alkynoates bearing *meta*-methoxyl substituted phenoxy ring gave the product **4l** in 76% yield with complete regiocontrol.



In addition, different substituted aryl groups linked with the alkynyl could also be used to construct the 3-acyl-4-arylcoumarin derivatives in moderate to good yields (**4m-p**). Disappointingly, no desired product was observed when phenyl 2-octynoate was employed in the reaction.

Scheme 1. Cyclization of Phenyl Alkynoate **1a** with Various Aldehydes **2**^{a,b}



^a Reaction conditions: **1a** (0.25 mmol), **2** (1.0 mmol), TBAB (0.25 mmol), K₂S₂O₈ (0.5 mmol), DCE (1.5 mL) in a sealed tube under N₂ at 90 °C (oil bath) for 24 h. ^b Isolated yields.

Scheme 2. Cyclization of Various Alkynoates **1** with 4-Methoxybenzaldehyde **2c**^{a,b}




38
39
40
41
42
43

^a Reaction conditions: **1** (0.25 mmol), **2c** (4-methoxybenzaldehyde, 1.0 mmol), TBAB (0.25 mmol), $K_2S_2O_8$ (0.5 mmol), DCE (1.5 mL) in a sealed tube under N_2 at 90 °C (oil bath) for 24 h. ^b Isolated yields.


44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 3. Control Experiments.



To obtain a detailed mechanism for this transformation, some control experiments were performed. The intramolecular and intermolecular kinetic isotope effects ($k_H/k_D = 0.9$ and 1.3) were measured by using the deuterium labeled substrates [D₁]-**1a** and [D₅]-**1a** in competing experiments (Scheme 3). The observed low k_H/k_D values imply that the C-H bond cleavage is not the rate-limiting step in this process. Subsequently, a radical scavenger TEMPO or BHT (2,2,6,6-tetramethylpiperidinoxy or 2,6-di-tert-butyl-4-methylphenol) was added to the reaction mixture. The formation of **3a** was suppressed, and an adduct of *p*-tolualdehyde (**2a**) with TEMPO or BHT was detected from ESI-MS analysis (see supporting information). Thus, we inferred that the acylation/cyclization reaction may involve a radical mechanism.

Scheme 4. Possible Mechanism



27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Based on the results above and previous reports^{13, 17}, a plausible reaction mechanism via free-radical-type process is depicted in Scheme 4. Initially, the peroxydisulfate was reacted with TBAB to generate the bis(tetrabutylammonium) peroxydisulfate which could be readily converted into the tetrabutylammonium sulfate radical anions at high temperature.^{11k, 21} The tetrabutylammonium sulfate radical reacted with **2a** to form an acyl radical **A**. Selective addition of the radical **A** to the α -position of the C=O bond in alkyne **1a** generated the vinyl radical **B**. The intermediate **B** then cyclized to the arene to form the radical intermediate **C**. Subsequently, a single electron transfer from intermediate **C** to another sulfate radical could give cation **D** which was deprotonated by formed sulfate dianion to give the product **3a** and another bisulfate anion.

45
46
47
48
49
50
51
52
53
54
55

In summary, we have demonstrated a novel approach to the synthesis of biologically attractive 3-acyl-4-aryl-coumarins starting with readily prepared alkyneates and the commercially available aldehydes. Various 3-acyl-4-aryl-coumarins were selectively prepared in moderate to high yields. This method comprises an acylation with concomitant arene formation, providing a new, efficient and atom-economic route to the coumarin core structure. We anticipate further development of the presented method and its application towards synthesis of bioactive compounds.

56 57 58 59 60

EXPERIMENTAL SECTION

General Information. All reactions were performed under a N₂ atmosphere. Solvents were dried and degassed by standard methods before use. All alkynoates were synthesized according to reported procedures.²² Purification of the reaction products was carried out by column chromatography using silica gel. Analytical TLC was performed on a silica gel GF 254 Plate. NMR spectra were recorded on a 400MHz NMR spectrometer (400MHz for ¹H and 100MHz for ¹³C) using CDCl₃ and DMSO-d₆ as solution. Chemical shifts δ are reported in ppm relative to Me₄Si or residual CHCl₃. The multiplicity of signals is designated by the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). High resolution mass spectra (HRMS) were obtained on an MSD-Trap spectrometer with micromass MS software using electrospray ionisation (ESI). X-ray analysis were obtained with a X-ray single crystal diffractometer. Melting points were measured on microscopic apparatus and are uncorrected.

General Procedure for Carbon-cyclization of Alkynoates and Aldehydes.

Compound **1** (0.25 mmol), TBAB (0.25 mmol), K₂S₂O₈ (0.5 mmol) were added to a 25mL dried Schlenk tube with a magnetic bar and degassed with N₂ three times. Degassed 1,2-dichloroethane (1.5 mL) was added followed by the addition of aldehyde **2** (1.0 mmol). The tube was sealed and was stirred at 90 °C for the indicated time. The reaction mixture was diluted with EtOAc and filtered. The filtrate was concentrated under reduced pressure and then was purified by chromatography on silica gel (elute: EtOAc/Petroleum ether (bp 60-90 °C) 1/1 - 1/10, v/v) to give the desired product.

3-(4-Methylbenzoyl)-4-phenyl-2H-chromen-2-one (3a): 63.8 mg, 75%; yellow solid; mp 146-147 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, *J* = 8.1 Hz, 2H), 7.65-7.60 (m, 1H), 7.48 (d, *J* = 8.2 Hz, 1H), 7.37-7.35 (m, 3H), 7.32-7.26 (m, 4H), 7.18 (d, *J* = 8.0 Hz, 2H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃+DMSO-*d*₆): δ 191.0, 158.2, 152.9, 152.1, 144.4, 133.1, 132.1, 131.7, 128.9, 128.8, 128.7, 128.0, 127.9, 127.3, 125.3, 124.2, 118.8, 116.4, 21.2. HRMS (ESI): calcd for C₂₃H₁₇O₃⁺ [M+H]⁺ *m/z* 341.1172, found 341.1173.

3-Benzoyl-4-phenyl-2H-chromen-2-one (3b): 62.8 mg, 77%; yellow solid; mp 146-147 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 7.3 Hz, 2H), 7.63-7.58 (m, 1H), 7.51-7.44 (m, 2H), 7.37-7.29 (m, 5H), 7.28-7.22 (m, 4H), 7.18 (d, *J* = 8.0 Hz, 2H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃+ DMSO-*d*₆): δ 192.1, 158.7, 153.7, 152.9, 136.1, 133.8, 132.6, 132.2, 129.4, 129.2, 128.6, 128.5, 128.5, 127.9, 125.9, 124.6, 119.4, 117.1. HRMS (ESI): calcd for C₂₂H₁₅O₃⁺ [M+H]⁺ *m/z* 327.1016, found 327.1018.

3-(4-Methoxybenzoyl)-4-phenyl-2H-chromen-2-one (3c): 81.3 mg, 86%; yellow solid; mp 121-123 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 8.8 Hz, 2H), 7.62-7.58 (m, 1H), 7.45 (d, *J* = 8.3 Hz, 1H), 7.34-7.32 (m, 3H), 7.29-7.22 (m, 4H), 6.83 (d, *J* = 8.8 Hz, 2H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃+ -DMSO-*d*₆): δ

1
2
3 190.1, 163.8, 158.5, 153.2, 152.1, 132.2, 131.9, 131.3, 129.1, 128.9, 128.2, 128.1,
4 127.5, 125.7, 124.3, 119.0, 116.6, 113.5, 55.1. HRMS (ESI): calcd for $C_{23}H_{16}O_4^+$
5 $[M+Na]^+$ m/z 379.0941, found 379.0937.

6
7 3-(4-Fluorobenzoyl)-4-phenyl-2H-chromen-2-one (**3d**): 73.1 mg, 85%; yellow solid;
8 mp 179-181 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.84-7.80 (m, 2H), 7.65-7.60 (m, 1H),
9 7.47 (d, $J = 8.3$ Hz, 3H), 7.36-7.34 (m, 3H), 7.31-7.24 (m, 4H), 7.03 (d, $J = 8.3$ Hz,
10 3H), 2.32 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 190.5, 166.1 (d, $J_{C-F} = 254.9$ Hz),
11 158.7, 153.7, 153.1, 132.8, 132.7 (d, $J_{C-F} = 3.1$ Hz), 132.2, 131.9 (d, $J_{C-F} = 9.6$ Hz),
12 129.6, 128.6, 128.6, 127.9, 125.6, 124.7, 119.3, 117.2, 115.8 (d, $J_{C-F} = 22.0$ Hz).
13 HRMS (ESI): calcd for $C_{22}H_{14}FO_3^+$ $[M+H]^+$ m/z 345.0921, found 345.0922.

14
15 3-(4-Chlorobenzoyl)-4-phenyl-2H-chromen-2-one (**3e**): 63.0 mg, 70%; yellow solid;
16 mp 180-182 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.73 (d, $J = 8.6$ Hz, 2H), 7.64-7.59
17 (m, 1H), 7.46 (d, $J = 8.2$ Hz, 1H), 7.36-7.31 (m, 5H), 7.29-7.23 (m, 4H). ^{13}C NMR
18 (100 MHz, $CDCl_3$): δ 190.9, 158.6, 153.7, 153.3, 140.3, 134.5, 132.9, 132.1, 130.5,
19 129.6, 128.9, 128.6, 128.6, 127.9, 125.4, 124.7, 119.3, 117.2. HRMS (ESI): calcd for
20 $C_{22}H_{14}ClO_3^+$ $[M+H]^+$ m/z 361.0626, found 361.0627.

21
22 3-(4-Bromobenzoyl)-4-phenyl-2H-chromen-2-one (**3f**): 69.7 mg, 69%; yellow solid;
23 mp 182-183 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.66-7.60 (m, 3H), 7.51-7.45 (m, 3H),
24 7.36-7.34 (m, 3H), 7.32-7.23 (m, 4H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 191.1, 158.7,
25 153.7, 153.4, 134.9, 132.9, 132.1, 131.9, 130.6, 129.7, 129.2, 128.7, 128.6, 128.0,
26 125.4, 124.7, 119.3, 117.2. HRMS (ESI): calcd for $C_{22}H_{14}BrO_3^+$ $[M+H]^+$ m/z
27 405.0121, found 405.0120.

28
29 4-Phenyl-3-(4-trifluoromethylbenzoyl)-2H-chromen-2-one (**3g**): 37.4 mg, 38%;
30 yellow solid; mp 169-171 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.89 (d, $J = 8.0$ Hz, 2H),
31 7.66-7.61 (m, 3H), 7.36-7.32 (m, 3H), 7.30-7.25 (m, 4H). ^{13}C NMR (100 MHz,
32 $CDCl_3$): δ 191.2, 158.6, 153.9, 153.8, 138.9, 134.8 (q, $J_{C-F} = 32.5$ Hz), 133.1, 132.1,
33 129.7, 129.4, 128.7, 128.6, 128.1, 125.7 (q, $J_{C-F} = 3.7$ Hz), 125.2, 124.8, 123.4 (q, J_{C-F}
34 = 271.6 Hz), 119.3, 117.3. HRMS (ESI): calcd for $C_{23}H_{14}F_3O_3^+$ $[M+H]^+$ m/z
35 395.0890, found 395.0893.

36
37 3-(3-Methylbenzoyl)-4-phenyl-2H-chromen-2-one (**3h**): 63.8 mg, 75%; yellow solid;
38 mp 99-100 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.63-7.57 (m, 3H), 7.47 (d, $J = 8.2$ Hz,
39 1H), 7.34-7.33 (m, 3H), 7.30 (s, 1H), 7.28-7.22 (m, 5H), 2.32 (s, 3H). ^{13}C NMR (100
40 MHz, $CDCl_3$): δ 192.2, 158.7, 153.6, 152.7, 138.3, 136.1, 134.6, 132.6, 132.3, 129.5,
41 129.4, 128.6, 128.5, 128.4, 127.9, 126.6, 126.1, 124.6, 119.4, 117.1, 21.1. HRMS
42 (ESI): $C_{23}H_{17}O_3^+$ $[M+H]^+$ m/z 341.1172, found 341.1174.

43
44 3-(3-Methoxybenzoyl)-4-phenyl-2H-chromen-2-one (**3i**): 64.0 mg, 72%; yellow
45 solid; mp 100-101 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.63-7.59 (m, 1H), 7.47-7.44
46 (m, 1H), 7.37-7.33 (m, 5H), 7.30-7.24 (m, 5H), 7.06-7.03 (m, 1H), 3.78 (s, 3H). ^{13}C
47 NMR (100 MHz, $CDCl_3$): δ 191.9, 159.7, 158.7, 153.6, 152.8, 137.4, 132.6, 132.2,
48 129.5, 129.4, 128.6, 128.5, 127.9, 125.9, 124.6, 122.4, 120.5, 119.3, 117.1, 112.7,
49 55.3. HRMS (ESI): calcd for $C_{23}H_{17}O_4^+$ $[M+H]^+$ m/z 357.1121, found 357.1122.

50
51 3-(3-Chlorobenzoyl)-4-phenyl-2H-chromen-2-one (**3j**): 44.1 mg, 49%; yellow solid;
52 mp 110-113 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.74 (s, 1H), 7.67-7.61 (m, 2H),
53
54
55
56
57
58
59
60

7.48-7.44 (m, 2H), 7.36-7.34 (m, 3H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.26-7.24 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 190.9, 158.6, 153.7, 153.5, 127.7, 134.8, 133.6, 132.9, 132.1, 129.9, 129.6, 128.9, 128.6, 128.6, 128.0, 127.3, 125.2, 124.7, 119.2, 117.2. HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{14}\text{ClO}_3^+$ $[\text{M}+\text{H}]^+$ m/z 361.0626, found 361.0628.

3-(3,4-Dimethylbenzoyl)-4-phenyl-2H-chromen-2-one (3k): 48.7 mg, 55%; yellow solid; mp 180-182 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.63-7.58 (m, 2H), 7.53 (d, $J = 7.8$ Hz, 1H), 7.46 (d, $J = 8.3$ Hz, 1H), 7.35-7.33 (m, 3H), 7.30-7.25 (m, 3H), 7.23 (d, $J = 7.8$ Hz, 1H), 7.12 (d, $J = 7.8$ Hz, 1H), 2.26 (s, 3H), 2.23 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 191.8, 158.8, 153.6, 152.5, 143.7, 136.9, 134.1, 132.5, 132.4, 130.1, 129.8, 129.3, 128.6, 128.5, 127.9, 127.2, 126.2, 124.5, 119.5, 117.1, 20.1, 19.6. HRMS (ESI): calcd for $\text{C}_{24}\text{H}_{19}\text{O}_3^+$ $[\text{M}+\text{H}]^+$ m/z 355.1329, found 355.1330.

3-(2-Methylbenzoyl)-4-phenyl-2H-chromen-2-one (3l): 57.0 mg, 67%; yellow solid; mp 160-162 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.62-7.55 (m, 2H), 7.45 (d, $J = 8.3$ Hz, 1H), 7.33-7.29 (m, 4H), 7.23-7.19 (m, 4H), 7.14 (d, $J = 7.6$ Hz, 1H), 7.10 (d, $J = 7.3$ Hz, 1H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 193.7, 158.8, 153.7, 152.2, 140.1, 135.9, 132.6, 132.4, 132.4, 131.9, 131.0, 129.3, 128.5, 128.4, 127.5, 125.5, 125.4, 124.6, 119.6, 117.1, 21.2. HRMS (ESI): calcd for $\text{C}_{23}\text{H}_{17}\text{O}_3^+$ $[\text{M}+\text{H}]^+$ m/z 341.1172, found 341.1172.

3-(2-Hydroxybenzoyl)-4-phenyl-2H-chromen-2-one (3m): 47.0 mg, 55%; yellow solid; mp 179-181 °C. ^1H NMR (400 MHz, CDCl_3): δ 11.51 (s, 1H), 7.65-7.61 (m, 1H), 7.51-7.45 (m, 2H), 7.42-7.24 (m, 8H), 6.89 (d, $J = 8.4$ Hz, 1H), 6.79 (d, $J = 7.6$ Hz, 1H). ^{13}C NMR (100 MHz, $\text{CDCl}_3+\text{DMSO}-d_6$): δ 197.0, 162.1, 158.1, 153.1, 152.8, 136.9, 132.7, 131.7, 131.6, 129.4, 128.3, 128.1, 127.7, 124.5, 123.9, 119.3, 118.9., 118.7, 117.8, 116.8. HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{15}\text{O}_4^+$ $[\text{M}+\text{H}]^+$ m/z 343.0965, found 343.0972.

3-(2,4-Dichlorobenzoyl)-4-phenyl-2H-chromen-2-one (3n): 51.2 mg, 52%; yellow solid; mp 119-121 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.64-7.58 (m, 1H), 7.46-7.43 (m, 2H), 7.29 (d, $J = 1.8$ Hz, 1H), 7.24-7.22 (m, 4H), 7.15 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 189.7, 158.3, 153.7, 138.8, 134.9, 133.5, 133.0, 132.4, 130.3, 129.5, 128.6, 128.3 (2C), 128.2, 127.3, 126.6, 124.6, 119.5, 117.1. HRMS (ESI): calcd for $\text{C}_{22}\text{H}_{13}\text{Cl}_2\text{O}_3^+$ $[\text{M}+\text{H}]^+$ m/z 395.0236, found 395.0235.

3-Butyryl-4-phenyl-2H-chromen-2-one (3o): 41.6 mg, 57%; yellow solid; mp 72-73 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.59-7.55 (m, 1H), 7.50-7.49 (m, 3H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.32-7.31 (m, 2H), 7.25-7.22 (m, 2H), 2.45 (t, $J = 7.2$ Hz, 2H), 1.52-1.42 (m, 2H), 0.70 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 201.7, 158.5, 153.4, 151.3, 132.5, 132.4, 129.6, 128.8, 128.7, 128.4, 127.9, 124.5, 119.4, 117.0, 45.5, 16.5, 13.3. HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{17}\text{O}_3^+$ $[\text{M}+\text{H}]^+$ m/z 293.1172, found 293.1178.

3-(3-Methylbutanoyl)-4-phenyl-2H-chromen-2-one (3p): 46.7 mg, 61%; yellow solid; mp 107-109 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.59-7.55 (m, 1H), 7.51-7.49 (m, 3H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.33-7.31 (m, 2H), 7.21 (d, $J = 4.2$ Hz, 2H), 2.36 (d, $J = 6.8$ Hz, 2H), 2.09-2.01 (m, 1H), 0.70 (d, $J = 6.4$ Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 201.1, 158.5, 153.3, 151.2, 132.5, 132.3, 129.6, 128.8, 128.7, 128.0, 127.9,

1
2
3 124.5, 119.4, 116.9, 52.4, 23.4, 22.2. HRMS (ESI): calcd for $C_{20}H_{19}O_3^+$ $[M+H]^+$ m/z
4 307.1329, found 307.1337.

5
6 *3-(Cyclopropanecarbonyl)-4-phenyl-2H-chromen-2-one (3q)*: 26.8 mg, 37%;
7 yellow solid; mp 127-128 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.60-7.56 (m, 1H),
8 7.50-7.48 (m, 3H), 7.29 (d, $J = 8.0$ Hz, 1H), 7.35-7.32 (m, 2H), 7.29-7.20 (m, 2H),
9 2.08-2.02 (m, 1H), 0.99-0.94 (m, 1H), 0.83-0.78 (m, 1H). ^{13}C NMR (100 MHz,
10 $CDCl_3$): δ 201.5, 158.4, 153.5, 151.9, 132.9, 132.6, 129.5, 128.8, 128.1 (2C), 124.5,
11 119.4, 117.0, 23.1, 12.7. HRMS (ESI): calcd for $C_{19}H_{15}O_3^+$ $[M+H]^+$ m/z 291.1016,
12 found 291.1016.

13
14
15
16 *3-(4-Methoxybenzoyl)-6-methyl-4-phenyl-2H-chromen-2-one (4a)*: 74.0 mg, 80%;
17 yellow solid; mp 80 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.76 (d, $J = 8.8$ Hz, 2H),
18 7.33-7.31 (m, 3H), 7.26-7.24 (m, 3H), 7.15 (d, $J = 8.0$ Hz, 1H), 7.04 (d, $J = 8.0$ Hz,
19 1H), 6.81 (d, $J = 8.8$ Hz, 2H), 3.80 (s, 3H), 2.47 (s, 3H). ^{13}C NMR (100 MHz,
20 $CDCl_3$): δ 190.6, 163.9, 159.1, 153.7, 152.5, 143.9, 132.6, 131.6, 129.4, 129.3, 128.6,
21 128.4, 127.5, 125.7, 124.9, 117.2, 116.9, 113.8, 55.4, 21.6. HRMS (ESI): calcd for
22 $C_{24}H_{19}O_4^+$ $[M+H]^+$ m/z 371.1278, found 371.1284.

23
24
25
26 *6-t-Butyl-3-(4-methoxybenzoyl)-4-phenyl-2H-chromen-2-one (4b)*: 79.3 mg, 77%;
27 yellow solid; mp 106-107 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.77 (d, $J = 8.8$ Hz, 2H),
28 7.46 (s, 1H), 7.33-7.26 (m, 6H), 7.21 (d, $J = 8.4$ Hz, 1H), 6.81 (d, $J = 8.8$ Hz, 2H),
29 3.81 (s, 3H), 1.37 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 190.6, 163.9, 159.2, 157.2,
30 153.7, 152.4, 132.6, 131.6, 129.5, 129.3, 128.6, 128.4, 127.4, 125.2, 122.1, 116.9,
31 113.8, 113.8, 55.4, 35.2, 30.9. HRMS (ESI): calcd for $C_{27}H_{25}O_4^+$ $[M+H]^+$ m/z
32 413.1747, found 413.1751.

33
34
35 *3-(4-Methoxybenzoyl)-6-methoxyl-4-phenyl-2H-chromen-2-one (4c)*: 39.6 mg, 41%;
36 yellow solid; mp 155-156 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.77 (d, $J = 8.8$ Hz, 2H),
37 7.33-7.31 (m, 3H), 7.26-7.22 (m, 2H), 7.17 (d, $J = 8.9$ Hz, 1H), 6.93 (d, $J = 2.4$ Hz,
38 1H), 6.83-6.78 (m, 3H), 3.90 (s, 3H), 3.81 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ
39 190.8, 163.9, 163.3, 159.2, 155.5, 152.9, 132.8, 131.7, 129.7, 129.3, 128.9, 128.6,
40 128.4, 122.9, 113.8, 112.9, 112.8, 100.9, 55.9, 55.4. HRMS (ESI): calcd for
41 $C_{24}H_{19}O_5^+$ $[M+H]^+$ m/z 387.1227, found 387.1230.

42
43
44 *3-(4-Methoxybenzoyl)-6-phenoxy-4-phenyl-2H-chromen-2-one (4d)*: 88.4 mg, 79%;
45 yellow solid; mp 145-146 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.77 (d, $J = 8.8$ Hz, 2H),
46 7.43 (t, $J = 7.7$ Hz, 2H), 7.34-7.32 (m, 3H), 7.26-7.25 (m, 3H), 7.21 (d, $J = 8.9$ Hz,
47 1H), 7.11 (d, $J = 8.0$ Hz, 2H), 6.95 (d, $J = 2.3$ Hz, 1H), 6.87 (dd, $J_1 = 8.8$ Hz, $J_2 = 2.3$
48 Hz, 1H), 6.83 (d, $J = 8.8$ Hz, 2H), 3.82 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 190.6,
49 164.1, 161.9, 158.9, 155.2, 154.9, 152.6, 132.7, 131.7, 130.2, 129.6, 129.4, 129.3,
50 128.6, 128.5, 128.3, 125.3, 123.9, 120.4, 119.2, 114.5, 114.4, 113.8, 105.1, 55.5.
51 HRMS (ESI): calcd for $C_{29}H_{21}O_5^+$ $[M+H]^+$ m/z 449.1384, found 449.1386.

52
53
54 *6-Fluoro-3-(4-methoxybenzoyl)-4-phenyl-2H-chromen-2-one (4e)*: 73.8 mg, 79%;
55 yellow solid; mp 143-144 °C. 1H NMR (400 MHz, $CDCl_3$): δ 7.76 (d, $J = 8.8$ Hz, 2H),
56 7.35-7.33 (m, 3H), 7.29-7.26 (m, 3H), 7.17 (dd, $J_1 = 8.8$ Hz, $J_2 = 2.3$ Hz, 1H), 6.87
57 (td, $J_1 = 8.4$ Hz, $J_2 = 2.2$ Hz, 1H), 6.83 (d, $J = 8.8$ Hz, 2H), 3.82 (s, 3H). ^{13}C NMR
58
59
60

(100 MHz, CDCl₃): δ 190.1, 164.8 (d, $J = 254.1$ Hz), 164.2, 158.5, 154.8 (d, $J = 15.8$ Hz), 152.1, 132.3, 131.7, 129.7 (d, $J = 10.2$ Hz), 129.6, 129.3, 128.6, 128.5, 125.1 (d, $J = 2.9$ Hz), 116.3 (d, $J = 2.8$ Hz), 113.9, 112.7 (d, $J = 22.3$ Hz), 104.6 (d, $J = 25.5$ Hz), 55.4. HRMS (ESI): calcd for C₂₃H₁₆FO₄⁺ [M+H]⁺ m/z 375.1027, found 375.1027.

6-Chloro-3-(4-methoxybenzoyl)-4-phenyl-2H-chromen-2-one (4f): 68.3 mg, 70%; yellow solid; mp 171 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, $J = 8.7$ Hz, 2H), 7.45 (s, 3H), 7.34-7.29 (m, 3H), 7.25-7.20 (m, 4H), 6.82 (d, $J = 8.8$ Hz, 2H), 3.80 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.0, 164.2, 158.2, 153.8, 151.8, 138.5, 132.0, 131.7, 129.6, 129.1, 128.8, 128.6, 128.5, 126.0, 125.1, 118.1, 117.3, 113.9, 55.4. HRMS (ESI): calcd for C₂₃H₁₆ClO₄⁺ [M+H]⁺ m/z 391.0732, found 391.0734.

6-Bromo-3-(4-methoxybenzoyl)-4-phenyl-2H-chromen-2-one (4g): 80.3 mg, 74%; yellow solid; mp 147-148 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, $J = 8.8$ Hz, 2H), 7.62 (d, $J = 1.4$ Hz, 1H), 7.37-7.33 (m, 4H), 7.25 (t, $J = 4.1$ Hz, 2H), 7.13 (d, $J = 8.6$ Hz, 1H), 6.83 (d, $J = 8.8$ Hz, 2H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.0, 164.2, 158.2, 153.7, 151.9, 131.9, 131.7, 129.6, 129.1, 128.8, 128.6, 128.5, 127.9, 126.6, 126.2, 120.3, 118.5, 113.9, 55.4. HRMS (ESI): calcd for C₂₃H₁₆BrO₄⁺ [M+H]⁺ m/z 435.0226, found 435.0231.

3-(4-Methoxybenzoyl)-4-phenyl-6-trifluoromethyl-2H-chromen-2-one (4h): 57.2 mg, 54%; yellow solid; mp 141-142 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, $J = 8.8$ Hz, 2H), 7.70 (s, 3H), 7.47 (d, $J = 8.4$ Hz, 1H), 7.42 (d, $J = 8.2$ Hz, 1H), 7.37-7.35 (m, 3H), 7.27-7.26 (m, 2H), 6.83 (d, $J = 8.8$ Hz, 2H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 189.6, 164.3, 157.9, 153.2, 151.1, 133.9 (d, $J_{C-F} = 33.4$ Hz), 132.3, 131.7, 130.2, 129.8, 128.7, 128.7, 128.6, 122.2, 123.0 (d, $J_{C-F} = 271.3$ Hz), 121.0 (d, $J_{C-F} = 3.5$ Hz), 114.5 (d, $J_{C-F} = 4.0$ Hz), 114.0, 113.7, 55.5. HRMS (ESI): calcd for C₂₄H₁₆F₃O₄⁺ [M+H]⁺ m/z 425.0995, found 425.0997.

5,7-Dimethyl-3-(4-methoxybenzoyl)-4-phenyl-2H-chromen-2-one (4i): 54.7 mg, 57%; yellow solid; mp 188-189 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, $J = 8.8$ Hz, 2H), 7.33-7.31 (m, 3H), 7.27-7.24 (m, 3H), 6.85 (s, 1H), 6.81 (d, $J = 8.9$ Hz, 1H), 3.80 (s, 3H), 2.49 (s, 3H), 2.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.8, 163.9, 159.1, 152.7, 150.1, 134.9, 133.6, 132.7, 131.7, 129.4, 129.1, 128.6, 128.3, 126.2, 125.8, 125.2, 118.9, 113.7, 55.4, 20.8, 15.5. HRMS (ESI): calcd for C₂₅H₂₁O₄⁺ [M+H]⁺ m/z 385.1434, found 385.1436.

3-(4-Methoxybenzoyl)-7-methyl-4-phenyl-2H-chromen-2-one (4k) and *3-(4-Methoxybenzoyl)-5-methyl-4-phenyl-2H-chromen-2-one (4k')*: 78.6 mg, 85%; yellow solid. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, $J = 8.8$ Hz, 2H), 7.76 (d, $J = 8.8$ Hz, 2H), 7.45-7.38 (m, 2H), 7.35-7.30 (m, 7H), 7.30-7.26 (m, 4H), 7.15-7.08 (m, 2H), 7.03 (s, 1H), 6.82 (d, $J = 8.8$ Hz, 4H), 3.80 (s, 3H), 2.53 (s, 3H), 2.31 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.6, 190.6, 164.1, 159.0, 158.9, 152.8, 152.4, 151.9, 151.8, 134.4, 133.8, 133.5, 132.8, 132.6, 131.7, 131.7, 129.4, 129.3, 129.2, 128.6, 128.5, 128.4, 127.5, 126.6, 126.1, 125.6, 123.9, 119.2, 119.2, 116.9, 113.8, 113.8, 55.4, 20.9, 15.7. HRMS (ESI): calcd for C₂₄H₁₉O₄⁺ [M+H]⁺ m/z 371.1278, found 371.1281.

1
2
3 *3-(4-Methoxybenzoyl)-7-methoxyl-4-phenyl-2H-chromen-2-one (4l)*: 73.3 mg, 76%;
4 yellow solid; mp 158 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, *J* = 8.8 Hz, 2H),
5 7.36 (d, *J* = 8.8 Hz, 1H), 7.32-7.26 (m, 4H), 7.16 (dd, *J*₁ = 8.8 Hz, *J*₂ = 2.9 Hz, 1H),
6 6.80 (d, *J* = 8.8 Hz, 2H), 6.68 (d, *J* = 2.9 Hz, 1H), 3.78 (s, 3H), 3.68 (s, 3H). ¹³C NMR
7 (100 MHz, CDCl₃): δ 190.5, 164.0, 158.9, 156.1, 152.1, 147.9, 132.4, 131.6, 129.4,
8 129.3, 128.5, 126.4, 119.9, 119.6, 117.9, 113.8, 110.6, 55.7, 55.4. HRMS (ESI): calcd
9 for C₂₄H₁₉O₅⁺ [M+H]⁺ *m/z* 387.1227, found 387.1230.

10
11
12 *3-(4-Methoxybenzoyl)-4-(4-methoxyphenyl)-2H-chromen-2-one (4m)*: 57.8 mg,
13 60%, yellow solid; mp 150-151 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 8.7
14 Hz, 2H), 7.60-7.56 (m, 1H), 7.43 (d, *J* = 8.2 Hz, 1H), 7.35 (d, *J* = 7.8 Hz, 1H),
15 7.24-7.20 (m, 3H), 6.85-6.80 (m, 4H), 3.80 (s, 3H), 3.76 (s, 3H). ¹³C NMR (100 MHz,
16 CDCl₃): δ 190.7, 164.0, 160.3, 158.9, 153.6, 152.2, 132.4, 131.7, 130.2, 129.3, 127.9,
17 125.9, 124.5 (2H), 119.6, 117.1, 114.0, 113.8, 55.4, 55.2. HRMS (ESI): calculated for
18 C₂₄H₁₉O₅⁺ [M+H]⁺ *m/z* 387.1227, found 387.1228.

19
20
21 *3-(4-Methoxybenzoyl)-4-(4-methylphenyl)-2H-chromen-2-one (4n)*: 64.7 mg, 70%,
22 yellow solid; mp 132-133 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 8.8 Hz,
23 2H), 7.61-7.57 (m, 1H), 7.44 (d, *J* = 8.3 Hz, 1H), 7.34-7.31 (m, 1H), 7.27-7.22 (m,
24 1H), 7.18-7.12 (m, 4H), 6.84 (d, *J* = 8.9 Hz, 2H), 3.82 (s, 3H), 2.31 (s, 3H). ¹³C NMR
25 (100 MHz, CDCl₃): δ 190.7, 164.2, 159.0, 153.7, 152.8, 139.6, 132.5, 131.8, 129.5,
26 129.5, 129.3, 128.7, 128.0, 126.1, 124.6, 119.7, 117.2, 113.9, 55.5, 21.4. HRMS
27 (ESI): calculated for C₂₄H₁₉O₄⁺ [M+H]⁺ *m/z* 371.1278, found 371.1279.

28
29
30 *4-(4-Acetylphenyl)-3-(4-methoxybenzoyl)-2H-chromen-2-one (4o)*: 52.7 mg, 53%,
31 yellow solid; mp 157 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.94 (d, *J* = 8.0 Hz, 2H),
32 7.78 (d, *J* = 8.6 Hz, 2H), 7.65-7.60 (m, 1H), 7.47 (d, *J* = 8.3 Hz, 1H), 7.41-7.39 (m,
33 2H), 7.25 (d, *J* = 7.4 Hz, 1H), 7.18 (d, *J* = 7.7 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 3.83
34 (s, 3H), 2.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 197.2, 190.0, 164.4, 158.6,
35 153.7, 151.4, 137.6, 137.2, 132.8, 131.8, 129.2, 129.1, 128.5, 127.6, 126.6, 124.8,
36 119.1, 117.3, 114.1, 55.5, 26.6. HRMS (ESI): calculated for C₂₅H₁₉O₅⁺ [M+H]⁺ *m/z*
37 399.1227, found 399.1227.

38
39
40
41 *3-(4-Methoxybenzoyl)-4-(2-methylphenyl)-2H-chromen-2-one (4p)*: 74.0 mg, 80%,
42 yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 8.8 Hz, 2H), 7.60-7.56 (m, 1H),
43 7.45 (d, *J* = 8.0 Hz, 1H), 7.24-7.18 (m, 3H), 7.11-6.98 (m, 3H), 6.84 (d, *J* = 8.8 Hz,
44 2H), 3.81 (s, 3H), 2.14 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.0, 164.1, 159.0,
45 153.4, 153.2, 135.8, 132.5, 131.9, 131.5, 130.2, 129.3, 129.3, 128.2, 127.4, 126.5,
46 125.7, 124.7, 119.3, 117.0, 113.8, 55.4, 19.9. HRMS (ESI): calculated for C₂₄H₁₉O₄⁺
47 [M+H]⁺ *m/z* 371.1278, found 371.1279.

48
49
50
51 **Intramolecular Kinetic Isotope Effect (KIE) Study (Scheme 3)**. To a 25 mL
52 dried Schlenk tube were added alkynoate [D₁]-**1a** (0.25 mmol), TBAB (0.25 mmol),
53 K₂S₂O₈ (0.5 mmol), benzaldehyde **2b** (1.0 mmol), and DCE (1.5 mL) under a N₂
54 atmosphere. After sealing the tube, the reaction mixture was stirred at 90 °C for 6
55 hours after which time the reaction mixture was concentrated under reduced pressure.
56 The residue was purified by chromatography on silica gel to give the desired product
57
58
59
60

1
2
3 in 46% yield. The ratio of deuterium to hydrogen was determined from the ^1H NMR
4 relative integration values of H_a (7.26 ppm) based on H_b (7.61 ppm). (see Figure S1)

5
6 **Intermolecular Kinetic Isotope Effect (KIE) Study (Scheme 3).** To a 25mL
7 dried Schlenk tube were added alkynoate **1a** (0.125 mmol), $[\text{D}_1]\text{-1a}$ (0.125 mmol),
8 TBAB (0.25 mmol), $\text{K}_2\text{S}_2\text{O}_8$ (0.5 mmol), benzaldehyde **2b** (1.0 mmol), and DCE (1.5
9 mL) under a N_2 atmosphere. After sealing the tube, the reaction mixture was stirred at
10 90 °C for 6 hours after which time the reaction mixture was concentrated under
11 reduced pressure. The residue was purified by chromatography on silica gel to give
12 the desired product in 46% yield. The ratio of deuterium to hydrogen was determined
13 from the ^1H NMR relative integration values of H_b (7.61 ppm) based on H_a (7.79
14 ppm). (see Figure S2)

15
16
17
18
19 **Radical-trapping Experiments (Scheme 3).** Two equivalents of radical
20 scavenger (2,2,6,6-tetramethylpiperidinoxy or 2,6-di-tert-butyl-4-methylphenol) was
21 added to the reaction of **1a** with **2a** in the standard conditions. After two hours, the
22 reaction mixture was cooled to room temperature. The crude reaction mixture was
23 detected by ESI-MS, and no peak of the desired product was found. An adduct of
24 aldehyde with radical scavenger was detected shown in Figure S3 and S4.

25 ASSOCIATED CONTENT

26 Supporting Information

27 ^1H and ^{13}C NMR spectra of compounds **3** and **4** and crystal structure and data of **3a**.
28 This material is available free of charge via the Internet at <http://pubs.acs.org>.

29 Notes

30 The authors declare no competing financial interest.

31 ACKNOWLEDGEMENTS

32 This work was supported by the National Natural Science Foundation (NSF) of China
33 (no. 21172200 and 21302172).

34 REFERENCES

- 35 (1) Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. *Front. Med.*
36 *Chem.* **2009**, *4*, 23.
37 (2) (a) Goth, A. *Science* **1945**, *101*, 383. (b) Eckardt, T.; Hagen, V.; Schade, B.;
38 Schmidt, R.; Schweitzer, C.; Bendig, J. *J. Org. Chem.* **2002**, *67*, 703. (c) Wang, C. J.;
39 Hsieh, Y. J.; Chu, C. Y.; Lin, Y. Y.; Tseng, T. H. *Cancer Lett.* **2002**, *183*, 163. (d)
40 Zhao, Y.; Zheng, Q.; Dakin, K.; Xu, K.; Martinez, M. L.; Li, W. H. *J. Am. Chem. Soc.*
41 **2004**, *126*, 4653. (e) Komatsu, K.; Urano, Y.; Kojima, H.; Nagano, T. *J. Am. Chem.*
42 *Soc.* **2007**, *129*, 13447. (f) Signore, G.; Nifosi, R.; Albertazzi, L.; Storti, B.; Bizzarri,
43 R. *J. Am. Chem. Soc.* **2010**, *132*, 1276. (g) Wang, C.; Wu, C.; Zhu, J.; Miller, R. H.;
44 Wang, Y. *J. Med. Chem.*, **2011**, *54*, 2331. (h) Matos, M. J.; Vazquez-Rodriguez, S.;
45 Santana, L.; Uriarte, E.; Fuentes-Edfuf, C.; Santos, Y.; Munoz-Crego, A. *Molecules*,
46 **2013**, *18*, 1394.

(3) (a) Christie, R. M.; Lui, C. H. *Dyes Pigm.* **2000**, *47*, 79. (b) Schiedel, M. S.; Briehn, C. A.; Bauerle, P. *Angew. Chem. Int. Ed.* **2001**, *40*, 4677. (c) Uchiyama, S.; Takehira, K.; Yoshihara, T.; Tobita, S.; Ohwada, T. *Org. Lett.* **2006**, *8*, 5869. (d) Hirano, T.; Hiromoto, K.; Kagechika, H. *Org. Lett.* **2007**, *9*, 1315. (e) Turki, H.; Abid, S.; Fery-Forgues, S.; El Gharbi, R. *Dyes Pigm.* **2007**, *73*, 311.

(4) (a) Sastry, V. D. N.; Seshadri, T. R. *Proc. Ind. Acad. Sci.* 1942, *16A*, 29; *Chem. Abstr.* **1943**, *37*, 880. (b) Yamashita, M.; Okuyama, K.; Kawajiri, T.; Takada, A.; Inagaki, Y.; Nakano, H.; Tomiyama, M.; Ohnaka, A.; Teryama, I.; Kawasaki, I.; Ohta, S. *Tetrahedron* **2002**, *58*, 1497. (c) Nemeryuk, M. P.; Dimitrova, V. D.; Anisimova, O. S.; Sedov, A. L.; Soloveva, N. P.; Traven, V. F. *Chem. Heterocycl. Comp* **2003**, *39*, 1454.

(5) (a) Sandhu, S.; Bansal, Y.; Silakari, O.; Bansal, G. *Bioorg. Med. Chem.* **2014**, *22*, 3806. (b) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. *Curr. Med. Chem.* **2005**, *12*, 887.

(6) (a) Specht, D.-P.; Martic, P.-A.; Farid, S. *Tetrahedron* **1982**, *38*, 1203. (b) Raju, B.-C.; Tiwari, A.-K.; Kumar, J.-K.; Ali, A.-Z.; Agawane, S.-B.; Saidachary, G.; Madhusudana, K. *Bioorg. Med. Chem.* **2010**, *18*, 358. (c) Heravi, M.-M.; Poormohammad, N.; Beheshtiha, Y.-S.; Baghernejad, B.; Malakooti, R. *Chin. J. Chem.* **2009**, *27*, 968. (d) Heravi, M.-M.; Sadjadi, S.; Oskooie, H.-A.; Shoar, R.-H.; Bamoharram, F.-F. *Catal. Commun.* **2008**, *9*, 270. (e) Ranu, B.-C.; Jana, R. *Eur. J. Org. Chem.* **2006**, 3767. (f) Ajania, O. O.; Nwinyi, O. C. *J. Heterocycl. Chem.* **2010**, *47*, 179. (g) Tang, X.; Blake, A.-J.; Lewis, W.; Woodward, S. *Tetrahedron: Asymmetry* **2009**, *20*, 1881.

(7) (a) Surya P. R., H.; Sivakumar, S. *J. Org. Chem.* **2006**, *71*, 8715. (b) Yuan, H.-J.; Wang, M.; Liu, Y.-J.; Liu, Q. *Adv. Synth. Catal.* **2009**, *353*, 112. (c) Yuan, H.; Wang, M.; Liu, Y.; Wang, L.; Liu, J.; Liu, Q. *Chem. Eur. J.* **2010**, *16*, 13450.

(8) Majumdar, K.C.; Samanta, S.; Ansary, I.; Roy, B. *RSC Adv.* **2012**, *1*, 2137.

(9) Sun, H.; Zhang, Y.; Guo, F.; Yan, Y.; Wan, C.; Zha, Z.; Wang, Z. *Eur. J. Org. Chem.* **2012**, 480.

(10) (a) Li, C.-J. *Acc. Chem. Res.* **2009**, *42*, 335. (b) Mcglacken, G. P.; Bateman, L. M.; Bateman, L. *Chem. Soc. Rev.* **2009**, *38*, 2447. (c) Shabashov, D. *Acc. Chem. Res.* **2009**, *42*, 1074. (d) Ashenurst, J. A. *Chem. Soc. Rev.* **2010**, *39*, 540. (e) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068. (f) Le Bras, J.; Muzart, J. *Chem. Rev.* **2011**, *111*, 1170. (g) Liu, C.; Zhang, H.; Shi, W.; Lei, A. *Chem. Rev.* **2011**, *111*, 1780. (h) Xie, Y.-X.; Song, R.-J.; Xiang, J.-N.; Li, J.-H. *Chin. J. Org. Chem.* **2012**, *32*, 1555.

(11) For reviews, see: (a) Pan, C.; Jia, X.; Cheng, J. *Synthesis* **2012**, *44*, 677. For selected examples, see: (b) Tang, B.-X.; Song, R.-J.; Wu, C.-Y.; Liu, Y.; Zhou, M.-B.; Wei, W.-T.; Deng, G.-B.; Yin D.-L.; Li, J.-H. *J. Am. Chem. Soc.* **2010**, *132*, 8900. (c)

1
2
3 Jia, X.; Zhang, S.; Wang, W.; Luo, F.; Cheng, J. *Org. Lett.* **2009**, *11*, 3120. (d)
4 Chan, C.-W.; Zhou, Z.; Chan, A. S. C.; Yu, W.-Y. *Org. Lett.* **2010**, *12*, 3926. (e)
5 Basle, O.; Bidange, J.; Shuai, Q.; Li, C.-J. *Adv. Synth. Catal.* **2010**, *352*, 1145. (f)
6 Wang, P.; Rao, H.; Hua, R.; Li, C.-J. *Org. Lett.* **2012**, *14*, 902. (g) Zhou, B.; Yang, Y.;
7 Li, Y. *Chem. Commun.* **2012**, *48*, 5163. (h) Park, J.; Park, E.; Kim, A.; Lee, Y.; Chi,
8 K.-W.; Kwak, J.; Jung, Y.; Kim, I. *Org. Lett.* **2011**, *13*, 4390. (i) Sharma, S.; Park, E.;
9 Park, J.; Kim, I. *Org. Lett.* **2012**, *14*, 906. (j) Li, C.; Wang, L.; Li, P.; Zhou, W. *Chem.*
10 *Eur. J.* **2011**, *17*, 10208. (k) Shi, Z.; Glorius, F. *Chem. Sci.* **2013**, *4*, 829. (l) Chan,
11 C.-W.; Zhou, Z.; Yu, W.-Y. *Adv. Synth. Catal.* **2011**, *353*, 2999. (m) Sharma, S.; Park,
12 J.; Park, E.; Kim, A.; Kim, M.; Kwak, J.-H.; Jung, Y.-H.; Kim, I.-S. *Adv. Synth.*
13 *Catal.* **2013**, *355*, 332. (n) Yang, Y.; Zhou, B.; Li, Y. *Adv. Synth. Catal.* **2012**, *354*,
14 2916. (o) Matcha, K.; Antonchick, A.-P. *Angew. Chem. Int. Ed.* **2013**, *52*, 2082. (p)
15 Li, X.-A.; Wang, H.-L.; Yang, S.-D. *Org. Lett.* **2013**, *15*, 1794. (q) Wertz, S.; Leifert,
16 D.; Studer, A. *Org. Lett.* **2013**, *15*, 928.

17
18
19
20
21
22
23 (12) (a) Chudasama, V.; Fitzmaurice, R. J.; Caddick, S. *Nat. Chem.* **2010**, *2*, 592.
24 (b) Fitzmaurice, R. J.; Ahern, J.; Caddick, S. *Org. Biomol. Chem.* **2009**, *7*, 235. (c)
25 Tsujimoto, S.; Iwahama, T.; Sakaguchi, S.; Ishii, Y. *Chem. Commun.* **2001**, 2352. (d)
26 Tsujimoto, S.; Iwahama, T.; Sakaguchi, S.; Ishii, Y. *Tetrahedron Lett.* **2003**, *44*, 5601.
27 (e) Zhou, M.-B.; Song, R.-J.; Ouyang, X.-H.; Liu, Y.; Wei, W.-T.; Deng, G.-B.; Li,
28 J.-H. *Chem. Sci.* **2013**, *4*, 2690.

29
30
31 (13) Liu, W.; Li, Y.; Liu, K.; Li, Z. *J. Am. Chem. Soc.* **2011**, *133*, 10756.

32
33 (14) (a) Shi, Z.; Schröder, N.; Glorius, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 8092.
34 (b) Wang, J.; Liu, C.; Yuan, J.; Lei, A. *Angew. Chem. Int. Ed.* **2013**, *52*, 2256.

35
36 (15) For reviews, see: (a) Bosnich, B. *Acc. Chem. Res.* **1998**, *31*, 667. (b) Jun,
37 C.-H.; Hong, J.-B.; Lee, D. L. *Synlett* **1999**, 1. (c) Jun, C.-H.; Jo, E.-A.; Park, J.-W.
38 *Eur. J. Org. Chem.* **2007**, 1869. (d) Willis, M. C. *Chem. Rev.* **2010**, *110*, 725. (e)
39 Gonzalez-Rodriguez, C.; Willis, M. C. *Pure Appl. Chem.* **2011**, *83*, 577. (f) Leung, J.
40 C.; Krische, M. J. *Chem. Sci.* **2012**, *3*, 2202.

41
42 (16) For reviews, see: (a) Ouyang, K.; Xi, Z. *Acta Chim. Sin.* **2013**, *71*, 13. (b)
43 Shirakawa, E.; Hayashi, R. *Chem. Lett.* **2012**, *41*, 130. (c) Yanigasawa, S. Itami, K.
44 *Chem. Cat. Chem.* **2011**, *3*, 827. (d) Wang, Y. *Synlett.* **2011**, 2901.

45
46 (17) (a) Luo, J.-Y.; Hua, H.-L.; Chen, Z.-S.; Zhou, Z.-Z.; Yang, Y.-F.; Zhou, P.-X.;
47 He, Y.-T.; Liu, X.-Y.; Liang, Y.-M. *Chem. Commun.* **2014**, *50*, 1564. (b) Ouyang,
48 X.-H.; Song, R.-J.; Li, Y.; Liu, B.; Li, J.-H. *J. Org. Chem.* **2014**, *79*, 4582.

49
50 (18) Mi, X.; Wang, C.; Huang, M.; Zhang, J.; Wu, Y.; Wu, Y. *Org. Lett.* **2014**, *16*,
51 3356.

52
53 (19) For selected examples, see: (a) Chen, L.; Shi, E.; Liu, Z.; Chen, S.; Wei, W.;
54 Li, H.; Xu, K.; Wan, X. *Chem. Eur. J.* **2011**, *17*, 4085. (b) Wei, W.; Zhang, C.; Xu,
55
56
57
58
59
60

1
2
3 Y.; Wan, X. *Chem. Commun.* **2011**, 47, 10827. (c) Liu, Z.; Zhang, J.; Chen, S.; Shi,
4 E.; Xu, Y.; Wan, X. *Angew. Chem. Int. Ed.* **2012**, 51, 3231.

5
6 (20) This crystal was deposited in the Cambridge Crystallographic Data Centre
7 and assigned as CCDC 1022899.

8
9 (21) (a) Zhu, X.; Shi, Y.; Mao, H; Cheng Y.; Zhu, C. *Adv. Synth. Catal.* **2013**,
10 355, 3558. (b) Yang, S.-G.; Hwang, J.-P.; Park, M.-Y.; Lee, K.; Kim, Y.-H.
11 *Tetrahedron* **2007**, 63, 5184.

12
13 (22) Song, C. E.; Jung, D.; Choung, S. Y.; Roh, E. J.; Lee, S. *Angew. Chem. Int. Ed.*
14 **2004**, 43, 6183.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60